Description

About the Wolverine Blend

The Wolverine Blend is Velora Research’s pre-formulated stack of two of the most extensively studied tissue-research peptides, BPC-157 and TB-500. Each vial contains 5mg of the BPC-157 peptide and 5mg of TB-500 (10mg combined), lyophilized together for in vitro and preclinical research by qualified laboratories and research professionals.

The blend is supplied as a single lyophilized vial so researchers can run protocols that depend on a fixed BPC-157 to TB-500 ratio without weighing or combining two separately reconstituted compounds. Every batch is independently verified by a third-party analytical laboratory using high-performance liquid chromatography (HPLC) for purity and mass spectrometry for identity confirmation. The batch-specific Certificate of Analysis is published on our COAs page and linked from this product page.

What is BPC-157 peptide?

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a partial sequence of a larger body-protection compound found in human gastric juice. The published research literature characterizes BPC-157 across a broad set of preclinical models, including studies of tendon and ligament tissue, gastric mucosa, angiogenesis pathways, and growth-factor signaling in cell culture.

In published research, the BPC-157 peptide has been investigated for activity in the nitric-oxide pathway, vascular endothelial growth factor (VEGF) signaling, and interaction with the dopaminergic and serotonergic systems in animal models. It is not approved by the FDA for any therapeutic indication. Velora’s BPC-157 peptide is supplied solely as a research compound for in vitro and preclinical investigation.

What is TB-500?

TB-500 is a synthetic peptide derived from the actin-binding region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in cellular structure and migration. The TB-500 fragment used in research is typically a 17-amino-acid sequence centered on the LKKTETQ actin-binding motif, with a molecular weight of approximately 889 g/mol.

In preclinical literature, TB-500 has been characterized as an actin-modulating peptide with documented activity in cell-migration assays, angiogenesis models, and cell-culture studies of fibroblast behavior. Like BPC-157, TB-500 is not approved by the FDA for any therapeutic indication.

Why researchers pair BPC-157 with TB-500

The two compounds appear together in preclinical literature because they have been characterized as acting on complementary cellular pathways. Summary of the research rationale for the BPC-157 plus TB-500 pairing:

• BPC-157 peptide: published activity in growth-factor, nitric-oxide, and angiogenesis pathways across multiple preclinical models.
• TB-500: documented as an actin-binding peptide with characterized effects on cellular-migration and tissue-research assays.
• Combined research utility: the two compounds engage distinct molecular targets, which is why preclinical researchers often run protocols comparing the blend to either compound alone.

All mechanisms above are drawn from peer-reviewed preclinical and in-vitro literature. Velora Research supplies the Wolverine Blend solely for further investigation of these and related research questions in laboratory settings.

Key specifications:

Wolverine Blend pricing

Velora Research lists the Wolverine Blend at a single transparent tier. The blend is sized so a single vial typically covers an entire pilot protocol or a multi-arm cell-culture experiment without re-ordering:

Free US shipping applies on orders over $200, and most orders process within 1 to 2 business days. International orders are accepted in accordance with applicable research regulations.

What makes this among the best BPC-157 research stacks

Searchers looking for the best BPC-157 supply for laboratory research typically screen vendors on five criteria. Velora’s Wolverine Blend was built to meet all five:

• Verified individual-component purity. The Velora blend is not a pre-mixed bulk powder of unknown composition. Each component (BPC-157 and TB-500) is HPLC verified independently before blending, with both purity values reflected on the Certificate of Analysis.
• Documented BPC-157 molecular identity. Mass spectrometry confirms the pentadecapeptide identity of the BPC-157 component, ruling out the substitution risks (oxidized variants, truncated sequences, incorrect glutamate residues) that affect lower-grade supply.
• Lot traceability. Each batch is tied to a specific COA accessible by lot number, so any research result can be audited back to the exact verified compound used.
• Fixed-ratio blending. The 1:1 BPC-157 to TB-500 ratio is the most commonly cited blend ratio in published research, making the Wolverine Blend a drop-in substitute for protocols that specify this stack without separate reconstitution math.
• US shipping with cold-chain handling. BPC-157 and TB-500 are both temperature-sensitive in lyophilized form. Velora ships from US fulfillment with 2-day delivery to preserve peptide integrity in transit.

Why qualified researchers buy from Velora Research

• Batch-level third-party COA. Each lot of the BPC-157 peptide and TB-500 components is independently verified before blending.
• 99% or higher HPLC-verified purity per component. Identity, purity, and molecular integrity confirmed before any batch is released for sale.
• Documented production protocols. Lyophilized under controlled conditions, sealed in inert atmosphere, traceable from synthesis through shipment.
• US-based 2-day shipping. Free over $200; orders processed within 1 to 2 business days.
• Compliance-first sales policy. Sales restricted to qualified laboratories, institutions, and research professionals. Research-use-only terms acknowledged at checkout.

Reconstitution and storage guidance (research use)

The Wolverine Blend ships as a lyophilized powder containing 5mg of BPC-157 and 5mg of TB-500 (10mg combined) in a single vial. For in vitro studies, researchers typically reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a concentration matched to the assay protocol.

A common pilot ratio for the 10mg combined vial is 2 mL of bacteriostatic water, yielding a 5 mg/mL stock solution of the combined blend (2.5 mg/mL of each component). Adjust per study design.

• Pre-reconstitution: store sealed at -20°C in a dry, dark environment. Avoid freeze-thaw cycles, which can degrade peptide integrity.
• Post-reconstitution: refrigerate at 2 to 8°C and use within the stability window established by the research protocol. Single-use aliquots reduce repeated exposure to room temperature.
• Handling: reconstitute and aliquot under sterile lab conditions with appropriate PPE.

Velora Research supplies bacteriostatic water as a separate product. Please refer to the peer-reviewed literature for protocol-specific reconstitution and handling parameters.

BPC-157 alone vs. Wolverine Blend

Researchers evaluating the Wolverine Blend often weigh it against ordering the BPC-157 peptide separately. Summary of how the two purchase paths differ at the protocol level: